Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2017

16.01.2017 | Editorial

Challenges and Promises of Genetic Stratification of Risk in Multiple Myeloma

verfasst von: Hara Prasad Pati, Prashant Sharma

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

Multiple myeloma resembles solid tumours at several levels: it develops and progresses through a well-delineated sequence of pre-malignant and asymptomatic stages, it represents a genetically highly complex and heterogeneous disease, and the laboratory diagnosis of its genetic abnormalities stringently mandates specific testing of the malignant cells, and not the other non-neoplastic marrow components [1]. Also, in contrast to acute leukemias, a focussed testing approach using a single technique i.e. fluorescent in situ hybridization (FISH)-based cytogenetic studies, is highly informative in myeloma. However, FISH is best performed on flow cytometrically sorted plasma cells, or in conjunction with cytoplasmic immunoglobulin staining to ensure specificity [2]. Conventional metaphase cytogenetics in contrast is easier, but has a diminishing role in this disease since it primarily indicates plasma cell proliferation and is insensitive to several of the genetic lesions [3]. Newer molecular level techniques holding out the promise of greater prognostic information also loom on the horizon. …
Literatur
1.
Zurück zum Zitat Hervé AL, Florence M, Philippe M, Michel A, Thierry F, Kenneth A, Jean-Luc H, Nikhil M, Stéphane M (2011) Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol 29:1893–1897CrossRefPubMed Hervé AL, Florence M, Philippe M, Michel A, Thierry F, Kenneth A, Jean-Luc H, Nikhil M, Stéphane M (2011) Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol 29:1893–1897CrossRefPubMed
2.
Zurück zum Zitat Moore S, Suttle JM, Nicola M (2017) Cytoplasmic immunoglobulin light chain revelation and interphase fluorescence in situ hybridization in Myeloma. Methods Mol Biol 1541:127–142CrossRefPubMed Moore S, Suttle JM, Nicola M (2017) Cytoplasmic immunoglobulin light chain revelation and interphase fluorescence in situ hybridization in Myeloma. Methods Mol Biol 1541:127–142CrossRefPubMed
4.
Zurück zum Zitat Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK (2013) Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 122:4172–4181CrossRefPubMedPubMedCentral Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK (2013) Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 122:4172–4181CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, Ketterling RP, Lust JA, Kyle RA, Kumar SK (2013) Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27:1738–1744CrossRefPubMedPubMedCentral Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, Ketterling RP, Lust JA, Kyle RA, Kumar SK (2013) Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27:1738–1744CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Ross FM, Ibrahim AH, Vilain-Holmes A, Winfield MO, Chiecchio L, Protheroe RK, Strike P, Gunasekera JL, Jones A, Harrison CJ, Morgan GJ, Cross NC, UK Myeloma Forum (2005) Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia 19:1634–1642CrossRefPubMed Ross FM, Ibrahim AH, Vilain-Holmes A, Winfield MO, Chiecchio L, Protheroe RK, Strike P, Gunasekera JL, Jones A, Harrison CJ, Morgan GJ, Cross NC, UK Myeloma Forum (2005) Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia 19:1634–1642CrossRefPubMed
7.
Zurück zum Zitat Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK (2014) Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 28:398–403CrossRefPubMed Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK (2014) Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 28:398–403CrossRefPubMed
8.
Zurück zum Zitat Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H, International Myeloma Working Group (2014) IMWG consensus on risk stratification in multiple myeloma. Leukemia 28:269–277CrossRefPubMed Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H, International Myeloma Working Group (2014) IMWG consensus on risk stratification in multiple myeloma. Leukemia 28:269–277CrossRefPubMed
9.
Zurück zum Zitat Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr (2006) The molecular classification of multiple myeloma. Blood 108:2020–2028CrossRefPubMedPubMedCentral Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr (2006) The molecular classification of multiple myeloma. Blood 108:2020–2028CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23:6333–6338CrossRefPubMed Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23:6333–6338CrossRefPubMed
11.
Zurück zum Zitat Kamada Y, Sakata-Yanagimoto M, Sanada M, Sato-Otsubo A, Enami T, Suzukawa K, Kurita N, Nishikii H, Yokoyama Y, Okoshi Y, Hasegawa Y, Ogawa S, Chiba S (2012) Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis. Int J Hematol 96:492–500CrossRefPubMed Kamada Y, Sakata-Yanagimoto M, Sanada M, Sato-Otsubo A, Enami T, Suzukawa K, Kurita N, Nishikii H, Yokoyama Y, Okoshi Y, Hasegawa Y, Ogawa S, Chiba S (2012) Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis. Int J Hematol 96:492–500CrossRefPubMed
12.
Zurück zum Zitat Amend SR, Wilson WC, Chu L, Lu L, Liu P, Serie D, Su X, Xu Y, Wang D, Gramolini A, Wen XY, O’Neal J, Hurchla M, Vachon CM, Colditz G, Vij R, Weilbaecher KN, Tomasson MH (2015) Whole genome sequence of multiple myeloma-prone C57BL/KaLwRij mouse strain suggests the origin of disease involves multiple cell types. PLoS ONE 10:e0127828CrossRefPubMedPubMedCentral Amend SR, Wilson WC, Chu L, Lu L, Liu P, Serie D, Su X, Xu Y, Wang D, Gramolini A, Wen XY, O’Neal J, Hurchla M, Vachon CM, Colditz G, Vij R, Weilbaecher KN, Tomasson MH (2015) Whole genome sequence of multiple myeloma-prone C57BL/KaLwRij mouse strain suggests the origin of disease involves multiple cell types. PLoS ONE 10:e0127828CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D, Ganly P, Cocito F, Bignell G, Chapman MA, Sperling AS, Anderson KC, Avet-Loiseau H, Minvielle S, Campbell PJ, Munshi NC (2016) A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J 6:e467CrossRefPubMedPubMedCentral Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D, Ganly P, Cocito F, Bignell G, Chapman MA, Sperling AS, Anderson KC, Avet-Loiseau H, Minvielle S, Campbell PJ, Munshi NC (2016) A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J 6:e467CrossRefPubMedPubMedCentral
Metadaten
Titel
Challenges and Promises of Genetic Stratification of Risk in Multiple Myeloma
verfasst von
Hara Prasad Pati
Prashant Sharma
Publikationsdatum
16.01.2017
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2017
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-017-0778-z

Weitere Artikel der Ausgabe 1/2017

Indian Journal of Hematology and Blood Transfusion 1/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.